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Abstract
Background and aim of the study: Serum anti-Müllerian hormone (AMH) is a reliable marker of ovarian reserve,
and it has been shown to be correlated with reproductive outcomes in grouped analyses. However, practical data is
scarce for the physician and the patients to predict these outcomes in an individual couple according to serum AMH
measured prior to assisted reproduction technology (ART) procedures.
Study Design: To address this question, we performed an analytic observational study including 145 females
undergoing intracytoplasmic sperm injection (ICSI) in a single center. Results were analyzed according to serum
AMH; subgroup analyses were performed by grouping patients according to patient’s age and FSH levels.
Results: The risk of cycle cancelation decreased from 64% in patients with serum AMH ≤3 pmol/L (0.42 ng/mL) to
21% with AMH ≥15 pmol/L (2.10 ng/mL). Cycle cancelation occurred in approximately two-thirds of the patients with
AMH ≤ 3 pmol/L irrespective of the FSH level. However, with higher AMH values the risk of cycle cancelation
decreased more significantly in patients with normal FSH. The rate of good response increased from almost null in
patients with AMH ≤3 pmol/L to 61% in those with AMH ≥15 pmol/L. The positive correlation between good response
and AMH was also significant, but with lower absolute rates, when patients were grouped according to their age or
FSH levels. Pregnancy rate increased moderately, but significantly, from 31% with AMH ≤3 pmol/L to 35% with AMH
≥15 pmol/L.
Conclusions: We provide estimates of reproductive outcomes according to individualized values of serum AMH, in
general and in subgroups according to patient’s age or serum FSH, which are helpful for the clinician and the couple
in their decision making about starting an assisted reproductive treatment.
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Introduction
The human ovary contains a limited population of primordial
follicles, set approximately 20 weeks post-conception, when
the ovary follicle reserve achieves its maximum size.
Thereafter, the ovarian reserve decreases, having an impact
on natural fertility which clearly declines after the age of 30
years [1,2]. The age of women giving birth is increasing
worldwide due to diverse social reasons. Consequently, a
growing number of couples is facing age-related infertility
problems and seek medical assistance. Assisted reproductive
technology (ART) outcomes have improved over the years but
are limited by the ovarian response to hyperstimulation used in
treatment protocols. On the other hand, ART treatments are
expensive for healthcare systems or private practices and
represent a stressful situation for the couple. Therefore, the
necessity exists for optimization of the evaluation of the ovarian
reserve in order to minimize the uncertainty of the outcome of
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ART procedures. Age and circulating FSH levels, which have
classically been used to predict the fertility potential, lack
precision under specific clinical circumstances, especially
because there is a considerable variability regarding the
ovarian reserve amongst women of the same age [3].
The ovarian reserve is determined by the number of
primordial follicles present in the ovary and their quality.
Reliable markers of oocyte quality are yet to be developed, and
direct assessment of the pool of primordial follicles present in
the ovaries is not feasible. However, the number of antral
follicles represents a good estimator of the primordial follicle
pool and, therefore, of the quantitative aspect of the ovarian
reserve [4,5]. In the recent years, anti-Müllerian hormone
(AMH) has been shown to represent a reliable marker of the
ovarian reserve [6] and of the response to ovarian stimulation
[7–10]. A member of the TGFβ superfamily initially believed to
be a fetal testis hormone [11], AMH is also produced in the
ovary essentially by the granulosa cells of primary and small
antral follicles [12,13]. Serum AMH levels are clearly correlated
with the granulosa cells mass, ranging from undetectable in
normal post-menopause [14] and in Turner syndrome patients
with absence of gonadal tissue [15] to very high levels in
patients with polycystic ovary syndrome [16,17] or granulosa
cell tumors [18]. A particular advantage of AMH as a marker of
ovarian reserve is its insignificant variation during the
menstrual cycle [19–21], which does not restrict AMH
measurement to a particular stage of the cycle. The first in-
house AMH immunoassays developed in 1990 [22–24] were
replaced by commercial assays after 1998 [18,25,26]. The two
different commercially available AMH assays used in the
following 10 years showed clear differences in the reported
levels, mainly in the low female range [27], which complicates
the interpretation of the results for the clinician. Furthermore,
the large number of studies assessing the performance of
serum AMH as a predictor of the ovarian reserve and a
prognostic factor for the outcome of ART treatments have
mostly used only one cutoff value, as summarized in a recent
meta-analysis [5], thus dividing the population into two groups:
one below the cutoff value usually of homogeneously poor
prognosis, and another one above the cutoff value which is
extremely heterogeneous. Furthermore, although the effect of
age and of other reproductive variables on serum AMH has
been acknowledged for years, most of the studies have
analyzed serum AMH in the studied samples as a whole, or
after introducing complex correction factors in the statistical
analysis which hamper a simple interpretation of the AMH
value observed in an individual patient presenting to the
clinician.
The adequate identification of the responsiveness potential
specific for the serum AMH level in each patient before
entering an ART treatment may be most helpful for the couple
in order to decide whether to start treatment and for the
clinician in the proper management regarding the stimulation
protocol. The objective of this work was to provide the clinician
with a reliable tool to predict the most commonly used
reproductive outcomes in women undergoing
intracytoplasmatic sperm injection (ICSI) before starting the
procedure. To fulfill this objective we assessed the clinical
value of different serum levels AMH in predicting the rates of:
cycle cancelation, good response to ovarian stimulation,
syngamy, cleavage, implantation and clinical pregnancy. The
assessment was performed separately according to patients’
age (25-37 and 38-43 yr) and to serum FSH (normal or
elevated).
Methods
Study subjects and design
Subjects.  We performed an observational study,
retrospectively collecting data from 145 consecutive women,
aged 25 to 43 years-old, undergoing ICSI at Seremas Institute
(Buenos Aires, Argentina) between August 2009 and October
2010. The study was approved by the Seremas Institutional
Review Board. The need for written informed consent was
waived by the Institutional Review Board because, owing to the
retrospective observational design used, study results could
not modify any clinical decision made at the moment of ICSI
procedures.
Ovarian stimulation.  All patients were submitted to a
standard GnRH agonist protocol, and underwent controlled
ovarian hyperstimulation with recombinant FSH (Gonal-F;
Serono Laboratories, Switzerland). Ovulation was induced with
highly purified hCG (Ovidrel, Serono). Daily FSH doses and
timing of hCG administration were adjusted according to the
usual criteria of follicle maturation [28]. Follicle count was
performed by ultrasonography using a transvaginal probe.
Serum hormone levels.  Serum was obtained at first visit
for AMH measurement, and during ovarian stimulation on day 3
(d3) for FSH and E2 measurement and on the day of hCG
administration (d-hCG) for E2 measurement. AMH was
measured at the Centro de Investigaciones Endocrinológicas,
Hospital Ricardo Gutiérrez (Buenos Aires, Argentina), using an
ultrasensitive enzyme-linked immunoassay specific for human
AMH (EIA AMH/MIS®, Immunotech, Beckman-Coulter Co.,
Marseilles, France, ref. A11893), recently validated by our
group [29]. FSH and estradiol (E2) were measured by
chemiluminescence using Access® technology (Beckman
Coulter Inc.).
Intracytoplasmic sperm injection (ICSI).  Conventional
ICSI, as previously described [30], was conducted ~5 hours
post oocyte aspiration. Motile sperm were isolated using the
swim up technique. Around 2 µl of sperm were placed in 7%
polyvinylpyrrolidone and a sperm was injected into each oocyte
using standardized techniques. The embryos were cultured in a
single droplet containing 20 µl of medium and incubated at
37°C under controlled conditions (5% CO2, 5% O2 and 90%
N2). All embryo transfers were performed 72 hours after oocyte
aspiration. Since reproductive outcomes may be associated
with cycle rank (i.e. the number of previous ART cycles a
patient had already been submitted to) patients were included
only if they were in their first three attempts.
Outcome measures.  The main outcome measure was the
absolute risk (risk rate) of cycle cancelation (number of patients
with cancelled cycles divided by the total number of patients in
whom a cycle was initiated), good response to ovarian
stimulation (defined as ≥ 5 oocytes retrieved at the time of
Reproductive Outcomes According to Serum AMH
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aspiration), syngamy, cleavage at 48 h, multinucleated
embryos, implantation (defined as the number of gestational
sacs observed on ultrasound) and clinical pregnancy (defined
as the presence of fetal heart activity detected by ultrasound at
6 weeks) for each of the following serum AMH levels: 3, 6, 9,
12 and 15 pmol/L. Secondary outcome measures were the
predictive values of: patient’s age, serum FSH and estradiol on
d3, and serum estradiol and follicle count by ultrasound
assessment on d-hCG.
Statistical analyses
Data distribution was assessed for normality using the
Shapiro-Wilk test. Data of the risk rates of cycle cancelation,
good response to ovarian stimulation, syngamy, cleavage at 48
h, multinucleated embryos, implantation and clinical pregnancy
are presented with their 95% confidence intervals. Patient’s
age, basal serum AMH, FSH and estradiol, and serum estradiol
and follicle count by ultrasound assessment on the day of
ovulation induction by hCG administration are presented as the
median and interquartile range. Comparisons between 2
groups were made using an unpaired t test, except when a
non-Gaussian distribution was found, where a Mann-Whitney
test was used. Areas under the ROC curves were calculated
for age and hormone levels to estimate the predictive values
for the rates of: cycle cancelation, good response to ovarian
stimulation, syngamy, cleavage at 48 h, multinucleated
embryos, implantation and clinical pregnancy. Analyses wer
performed for the whole group, and independently according to
age, where the study cohort was divided into 2 groups (25-37
yr and 38-43 yr), or according to FSH levels, where the study
cohort was divided into 2 groups (FSH within the normal
reference range and FSH above the reference range). The
absolute risk values were compared using a one-sided Fisher’s
exact test. The level of significance was set at P <0.05. All
statistical analyses were performed using GraphPad Prism
version 5.01 for Windows (GraphPad Software, San Diego, CA,
USA).
Results
Cycle cancelation
In the whole group analyzed (Table 1), age and FSH was
significantly higher, and AMH was lower in patients with
cancelled cycles, as expected. No difference was observed in
E2. When patients were grouped by age (Table 2), the
significantly lower AMH and higher FSH values were still
observed in patients aged 38-43 yr with cancelled cycles.
When patients were classified according to their FSH levels
(Table 3), lower AMH levels were observed in patients with
cancelled cycles irrespective of their FSH levels. Serum AMH
showed excellent areas under the ROC curves to predict cycle
cancelation in the whole group and in the age and FSH
subgroups (Table 4). The absolute risk of cycle cancelation
was inversely correlated to serum AMH in the whole group
(Figure 1, A) and in the subgroups (Figure 1, B-E). The risk of
cycle cancelation in the whole group decreased from 64% in
patients with serum AMH ≤3 pmol/L (0.42 ng/mL) to 43% in
patients with AMH 6 pmol/L (0.84 ng/mL), 29% with AMH 9
pmol/L (1.26 ng/mL), 26% with AMH 12 pmol/L (1.68 ng/mL)
and 21% with AMH ≥15 pmol/L (2.10 ng/mL). When related to
patients with AMH <3 pmol/L (0.42 ng/mL), the relative risk of
cycle cancelation was 0.42 in patients with AMH between 6-9
pmol/L (0.84-1.26 ng/mL) and 0.37 in patients with AMH >15
pmol/L (>2.1 ng/mL) (Table 5). Interestingly, cycle cancelation
occurred in approximately two-thirds of the patients with AMH
≤3 pmol/L irrespective of the FSH level (Figure 1, D and E).
However, with higher AMH values the risk of cycle cancelation
decreased more significantly in patients with normal FSH.
Oocyte retrieval
The number of oocytes retrieved in non-cancelled cycles
increased progressively in correlation with serum AMH up to an
AMH level of 40 pmol/L (5.6 ng/mL) and plateaued thereafter
(Figure 2). The increase was observed irrespective of age or
serum FSH, yet with a lower absolute number of oocytes in
patients aged 38-43 years or with elevated FSH.
Serum AMH showed the most significant differences
between patients with good and poor response to stimulation,
i.e. retrieval of 5 or more oocytes (Tables 6, 7 and 8). Among
basal serum hormone determinations, AMH also showed areas
under the ROC curves of high performance to predict a good
response (Table 9).
Table 1. Characteristics of the whole study population with
cancelled and non-cancelled cycles.
 Non cancelled Cancelled P
n 114 31  
Age (yr) 34 (32-38) 38 (36-40) 0.003
AMH (pmol/L) 14.4 (8.6-24.9) 3.7 (<2.5-11.1) < 0.001
FSH (IU/L) 7.3 (5.9-9.2) 11.4 (7.5-16.8) 0.016
E2 (pg/ml) 47 (29-71) 43 (31-75) 0.871
Results are reported as median and interquartile range.
Comparisons between groups were made using a Mann-Whitney test.
doi: 10.1371/journal.pone.0075685.t001
Table 2. Characteristics of the whole study population with
cancelled and non-cancelled cycles, grouped by age.
 25-37 yr 38-43 yr
 
Non
cancelled Cancelled P
Non
cancelled Cancelled P
n 83 16  31 15  
Age (yr) 33 (31-35) 35 (31-37) 0.250 39 (38-41) 39 (38-40) 0.985
AMH
(pmol/L)
14.7
(8.9-27.2)
8.7
(3.5-19.9) 0.071
12.6
(7.5-22.5)
2.5
(<2.5-4.2)
<
0.001
FSH
(IU/L)
7.0
(6.1-9.2)
8.7
(7.4-13.8) 0.060
7.8
(5.3-9.4)
13.4
(7.1-22.7)  0.020
E2
(pg/ml) 45 (28-72) 44 (27-76) 0.993 49 (35-72) 43 (33-79) 1.000
Results are reported as median and interquartile range.
Comparisons between groups were made using a Mann-Whitney test.
doi: 10.1371/journal.pone.0075685.t002
Reproductive Outcomes According to Serum AMH
PLOS ONE | www.plosone.org 3 September 2013 | Volume 8 | Issue 9 | e75685
The rate of good response increased with serum AMH: it was
almost null in patients with AMH ≤3 pmol/L (0.42 ng/mL) in both
age groups (Figure 3) and rose up to 61% in those patients
with AMH 15 pmol/L (2.10 ng/mL). When related to patients
with AMH <3 pmol/L (0.42 ng/mL), the chances of good
response were approximately eight-fold higher in patients with
AMH between 6-12 pmol/L (0.84-1.68 ng/mL) and eleven-fold
higher in patients with AMH >15 pmol/L (>2.1 ng/mL) (Table 5).
The positive correlation between good response and AMH was
also significant, but with lower absolute rates, when patients
were grouped according to their age (Figure 3, B-C) or FSH
levels (Figure 3, D-E).
Syngamy, cleavage, implantation and pregnancy rates
No significant correlation was found between AMH levels
and the rates of syngamy (Spearman r -0.080, P=0.313),
cleavage at 48 h (Spearman r -0.004, P=0.623), multinucleated
embryos (Spearman r -0.062, P=0.457) or implantation
(Spearman r -0.053, P=0.557).
The rate of pregnancy showed an increase in correlation with
serum AMH in the whole group. Serum AMH was lower and
Table 3. Characteristics of the whole study population with
cancelled and non-cancelled cycles, grouped by FSH
levels.
 Normal FSH High FSH
 
Non
cancelled Cancelled P
Non
cancelled Cancelled P
N 86 9  28 22  
Age (yr) 34 (31-37) 37 (33-40) 0.246 36 (33-38) 38 (37-39) 0.039
AMH
(pmol/L)
16.3
(9.5-26.3)
6.4
(3.3-17.0) 0.017
11.9
(5.5-15.0)
<2.5
(<2.5-5.1) 0.005
FSH
(IU/L)
6.7
(5.5-7.9)
7.6
(5.6-9.2) 0.292
10.8
(9.6-13.2)
16.8
(13.7-23.8)  0.004
E2
(pg/ml) 48 (34-75) 71 (33-110) 0.348 44 (23-68) 40 (30-63) 0.922
Results are reported as median and interquartile range.
Comparisons between groups were made using a Mann-Whitney test.
doi: 10.1371/journal.pone.0075685.t003
Table 4. Areas under the ROC curve (± standard error) for
age and hormone levels to assess the value of serum AMH
as a predictor of cycle cancelation in the study population.
 All 25-37 yr 38-43 yr Normal FSH High FSH
Age 0.683 ±0.071
0.623 ±
0.121
0.504 ±
0.100
0.618 ±
0.103
0.753 ±
0.103
AMH 0.813 ±0.065
0.695 ±
0.108
0.928 ±
0.055
0.744 ±
0.103
0.848 ±
0.080
FSH 0.726 ±0.075
0.704 ±
0.092
0.765 ±
0.106
0.608 ±
0.102
0.857 ±
0.059
E2 0.514 ±0.080
0.502 ±
0.108
0.502 ±
0.127
0.626 ±
0.137
0.515 ±
0.109
doi: 10.1371/journal.pone.0075685.t004
age was higher in patients with a higher pregnancy rate when
the analysis was performed in the whole group (Table 10).
Interestingly, this was also observed in patients with high FSH
(Tables 11 and 12). A significantly positive correlation between
pregnancy rate and AMH was observed in the whole group
(Spearman r0.894, P=0.020, Figure 4 A), and in patients >38 yr
(Figure 4 C) or with high FSH (Figure 4 E).
Discussion
One of the most critical aspects before starting an ART
procedure is the initial evaluation of the female’s capacity to
produce healthy and developmental competent oocytes. Serum
AMH has become a standard determination to evaluate the
ovarian reserve. In the present study, we provide practical data
for the clinician and the couple to easily predict the odds for
cycle cancelation, good response to stimulation and
pregnancy, according to the level of circulating AMH in a
random sample obtained prior to initiating the ART procedure.
On the basis of the data provided in Figure 1, the clinician can
give practical counseling: risk of cycle cancelation attains
approximately two-thirds of the couples if serum AMH is 3
pmol/L, 1/3 if AMH is 9 pmol/L and 1/5 if AMH is 15 pmol/L.
Further discrimination can be made according to patient’s age
or serum FSH. Similarly, as shown in Figure 3, less than one-
twentieth of the attempts will yield a good response to
stimulation when serum AMH is 3 pmol/L, but the rate
increases to approximately 1/5 when AMH is 6 pmol/L,
approximately ½ when AMH is 9-12 pmol/L and almost 2/3
when AMH is 15 pmol/L. Many authors have previously
analyzed the association between serum AMH and
reproductive outcomes in women undergoing ART treatments,
as summarized in a recent systematic review [5]. Most of these
studies provide correlation coefficients or sensitivity and
specificity levels for a given AMH cutoff, using adequate
statistical procedures to avoid confounders. Although the
strength of the association has been unequivocally proven,
correlation coefficients or more complicate calculations do not
represent practical tools for straightforward application in
clinical practice. In the present work we have used a practical
approach and provide useful and easily applicable results of
serum AMH levels to predict the risk of cycle cancelation and
the chances of good response to controlled ovarian
hyperstimulation and pregnancy in females undergoing an ART
procedure, according to their age or FSH level. Some studies
have reported predictive values for poor response and
pregnancy rates, but only using 1 or 2 cutoff levels of serum
AMH [20,27,31–36]. Nelson and colleagues [37] reported more
discriminated prediction rates of oocyte retrieval and live births,
for five different serum AMH ranges. Here, we provide detailed
results for several reproductive outcomes helping to predict the
success rate of many steps of the ART procedure. One
particularly relevant, from a practical standpoint, is the
prediction of the risk of cycle cancelation, which has not been
analyzed by previous publications.
Our results are in line with those previously reported by other
authors showing that AMH is a useful marker for predicting
cycle cancelation [38] and poor response to ovarian stimulation
Reproductive Outcomes According to Serum AMH
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Figure 1.  Absolute risk (risk rate) of cancelled cycles as a function of AMH levels.  Patients were grouped according to age or
FSH levels. Rates are shown for serum AMH at 3, 6, 9, 12 and 15 pmol/L (equivalences for AMH in ng/mL are given below the X
axis of each graph). Dotted lines represent the 95% confidence interval.
doi: 10.1371/journal.pone.0075685.g001
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[5], representing a better predictor than the other classically
associated parameters such as FSH, estradiol and age [39].
Interestingly, our data show the special importance of serum
AMH in women aged >38 yr or with high serum FSH, and have
immediate application for the clinician and the patient in their
decision prior to start hormonal stimulation. For example, in
women 38-43 yr seeking for assisted reproduction treatment,
an AMH value ≥ 15 pmol/L (2.10 ng/mL) indicates a risk of 38%
to result in a cycle cancelation, and the risk increases to 83% if
AMH is ≤ 3 pmol/L (0.42 ng/mL). Also, different AMH values
are helpful for decision making in both patients with normal or
elevated FSH levels.
It is well established that AMH is correlated with the number
of oocytes retrieved at the time of aspiration [40]. Our results
are consistent with this observation, independently of the
patient’s age. Furthermore, from a practical standpoint, we
show that AMH is particularly useful to predict ovarian
response to stimulation, as shown by the best areas under the
ROC curves. Only E2-dhCG showed a better area under the
ROC curve; yet, it cannot be used as a predictor before starting
the stimulation protocol.
In our hands, AMH was not as powerful as a predictor of
oocyte quality in terms of fertilization rate, embryo development
and implantation. Although we found a correlation between
serum AMH and pregnancy rate in the whole group, the effect
magnitude was modest, in line with the controversial results
reported by other groups showing no [41–43] or moderate
usefulness of AMH in predicting embryo development [8,44].
However, it was interesting to note that AMH was more
discriminant in the high-risk groups, i.e. in the patients >38 yr or
with high FSH.
In conclusion, in an individual patient seeking for assisted
reproductive technology treatment, the serum AMH level
measured in a previous cycle can be used to predict the risk of
cycle cancelation and the chances of good ovarian response,
when analyzed together with patient’s age or serum FSH.
Serum AMH has a significantly better predictive value than
FSH and follicle count particularly in women > 38 yr.
Furthermore, serum AMH is useful to predict reproductive
outcomes in patients with a mild to moderate increase in FSH
levels. Although our study design does not allow us to conclude
that an infertility treatment should be interrupted on the basis of
low AMH, our results add to the existing evidence, and provide
practical information, on the usefulness of serum AMH level to
help clinicians and patients estimate the chances of good
treatment outcomes before initiating the stimulation protocol.
AMH evaluation is not routinely performed prior to stimulation
and should be incorporated into the initial screening of the
patient.
Table 5. Relative risk (RR) of cycle cancelation and good response (RR was considered as 1 in patients with AMH < 3
pmol/L).
 Cycle cancelation Good response
 RR 95%CI P RR 95%CI P
3.0-5.9 pmol/L 0.61 0.24-1.54 0.395 5.00 0.68-36.68 0.155
6.0-8.9 pmol/L 0.42 0.19-0.95 0.012 8.84 1.33-58-89 0.006
9.0-11.9 pmol/L 0.43 0.19-0.99 0.036 8.00 1.17-54.52 0.009
12.0-14.9 pmol/L 0.40 0.18-0.90 0.004 11.33 1.73-74.30 <0.001
≥ 15 pmol/L 0.37 0.17-0.81 <0.001 11.31 1.73-73.99 <0.001
doi: 10.1371/journal.pone.0075685.t005
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Figure 2.  Number of oocytes retrieved at the time of aspiration as a function of AMH levels (non-linear
regression).  Patients were grouped according to age or FSH levels.
doi: 10.1371/journal.pone.0075685.g002
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Table 6. Age, hormone levels and follicle count in the whole study population with good and poor response to controlled
ovarian hyperstimulation.
 Good response Poor response P
n 83 31  
Age (yr) 33 (31-37) 37 (34-40) 0.002
AMH (pmol/L) 15.9 (11.3-28.0) 4.6 (2.5-9.8) < 0.001
FSH (IU/L) 7.3 (5.9-8.7) 10.5 (6.4-16.8) 0.003
E2 (pg/ml) 46 (29-75) 45 (28-70) 0.667
E2-dhCG 1574 (1196-2273) 773 (521-1059) 0.002
Follicle count 7 (5-10) 3 (2-4) < 0.001
Results are reported as median and interquartile range.
Comparisons between groups were made using a Mann-Whitney test.
doi: 10.1371/journal.pone.0075685.t006
Table 7. Age, hormone levels and follicle count in patients with good and poor response to controlled ovarian
hyperstimulation, grouped by age.
 25-37 yr 38-43 yr
 Good response Poor response P Good response Poor response P
n 62 16  21 15  
Age (yr) 33 (31-35) 35 (33-37) 0.016 39 (38-40) 40 (38-41) 0.241
AMH (pmol/L) 18.3 (12.1-33.5) 5.8 (2.8-11.1) < 0.001 16.9 (9.5-24.3) 3.7 (<2.5-7.5) < 0.001
FSH (IU/L) 7.0 (6.1-8.7) 7.69 (6.0-12.6) 0.102 7.8 (5.3-8.1) 14.5 (6.8-19.0) 0.008
E2 (pg/ml) 45 (29-76) 45 (27-73) 0.825 53 (36-80) 46 (27-66) 0.410
E2-dhCG 1751 (1199-2504) 646 (400-1025) 0.003 1664 (1303-2254) 894 (555-1168) 0.023
Follicle count 8 (5-10) 3 (2-4) < 0.001 7 (5-9) 3 (2-4) 0.019
Results are reported as median and interquartile range.
Comparisons between groups were made using a Mann-Whitney test.
doi: 10.1371/journal.pone.0075685.t007
Table 8. Age, hormone levels and follicle count in patients with good and poor response to controlled ovarian
hyperstimulation, grouped by FSH levels.
 Normal FSH High FSH
 Good response Poor response P Good response Poor response P
n 68 17  15 14  
Age (yr) 31 (33-37) 37 (34-41) 0.029 34 (31-37) 38 (37-39) 0.007
AMH (pmol/L) 16.9 (11.1-28.3) 8.7 (3.6-11.2) < 0.001 13.2 (11.7-15.7) 2.7 (<2.5-5.8) < 0.001
FSH (IU/L) 6.7 (5.6-7.9) 6.9 (5.3-7.7) 0.76 10.1 (9.1-10.9) 16.8 (13.2-21.2) < 0.001
E2 (pg/ml) 46 (32-73) 57 (38-89) 0.337 48 (24-76) 40 (25-49)  0.359
E2-dhCG 1600 (1207-2478) 894 (761-1059) 0.004 1288 (1009-1916) 433 (111-1090)  0.045
Follicle count 8 (6-10) 3 (2-4) < 0.001 5 (5-10) 3 (2-4) 0.054
Results are reported as median and interquartile range.
Comparisons between groups were made using a Mann-Whitney test.
doi: 10.1371/journal.pone.0075685.t008
Reproductive Outcomes According to Serum AMH
PLOS ONE | www.plosone.org 8 September 2013 | Volume 8 | Issue 9 | e75685
Table 9. Areas under the ROC curve (± standard error) for age and hormone levels to assess the value of serum AMH as a
predictor of good response to controlled ovarian hyperstimulation in the study population.
 All 25-37 yr 38-43 yr Normal FSH High FSH
Age 0.683 ± 0.071 0.623 ± 0.121 0.504 ± 0.100 0.669 ± 0.073 0.793 ± 0.085
AMH 0.813 ± 0.065 0.695 ± 0.108 0.928 ± 0.055 0.783 ± 0.065 0.938 ± 0.041
FSH 0.726 ± 0.075 0.704 ± 0.092 0.765 ± 0.106 0.525 ± 0.080 0.976 ± 0.023
E2 0.514 ± 0.080 0.502 ± 0.108 0.502 ± 0.127 0.587 ± 0.088 0.602 ± 0.108
doi: 10.1371/journal.pone.0075685.t009
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Figure 3.  Absolute risk (risk rate) of good response to ovarian stimulation, defined as ≥ 5 oocytes retrieved at the time of
aspiration, as a function of AMH levels.  Patients were grouped according to age or FSH levels. Rates are shown for serum AMH
at 3, 6, 9, 12 and 15 pmol/L (equivalences for AMH in ng/mL are given at the bottom of the figure). Dotted lines represent the 95%
confidence interval.
doi: 10.1371/journal.pone.0075685.g003
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Table 10. Age, hormone levels and follicle count in the whole study population according to the achievement of clinical
pregnancy.
 Pregnancy Nonpregnancy P
n 35 89  
Age (yr) 33 (31-37) 36 (33-39) 0.028
AMH (pmol/L) 15.4 (12.0-32.6) 11.6 (5.9-21.5) 0.015
FSH (IU/L) 7.1 (5.2-9.1) 7.4 (6.2-9.7) 0.289
E2 (pg/ml) 47 (29-70) 49 (32-71) 0.964
E2-dhCG 1463 (1021-1944) 1391 (803-2264) 0.936
Follicle count 8 (5-10) 7 (4-9) 0.094
Results are reported as median and interquartile range.
Comparisons between groups were made using a Mann-Whitney test.
doi: 10.1371/journal.pone.0075685.t010
Table 11. Age, hormone levels and follicle count in patients, grouped by age, according to the achievement of clinical
pregnancy.
 25-37 yr 38-43 yr
 Pregnancy Nonpregnancy P Pregnancy Nonpregnancy P
n 27 59  8 30  
Age (yr) 32 (31-34) 34 (32-36) 0.067 39 (38-41) 40 (39-41) 0.263
AMH (pmol/L) 14.9 (12.1-33.3) 13.9 (7.5-22.8) 0.092 16.4 (7.7-21.9) 7.6 (3.7-15.4) 0.113
FSH (IU/L) 7.6 (5.7-9.3) 6.9 (5.6-8.7) 0.515 5.3 (4.5-7.9) 8.1 (7.1-14.5) 0.015
E2 (pg/ml) 37 (29-67) 50 (33-69) 0.495 64 (49-77) 43 (31-79) 0.135
E2-dhCG 1443 (876-1927) 1411 (923-2467) 0.456 1669 (1285-2229) 1243 (712-1862) 0.171
Follicle count 8 (6-10) 7 (4-10) 0.250 8 (4-10) 5 (3-9) 0.238
Results are reported as median and interquartile range.
Comparisons between groups were made using a Mann-Whitney test.
doi: 10.1371/journal.pone.0075685.t011
Table 12. Age, hormone levels and follicle count in patients, grouped by FSH levels, according to the achievement of clinical
pregnancy.
 Normal FSH High FSH
 Pregnancy Nonpregnancy P Pregnancy Nonpregnancy P
n 27 68  8 21  
Age (yr) 34 (31-38) 35 (32-38) 0.513 33 (31-34) 38 (37-39) < 0.001
AMH (pmol/L) 15.9 (12.0-32.6) 14.7 (7.8-25.1) 0.180 15.0 (7.1-36.6) 5.7 (<2.5-11.9) 0.008
FSH (IU/L) 6.3 (4.8-7.9) 6.7 (5.6-7.8) 0.356 9.9 (9.1-10.9) 13.1 (10.4-18.3) 0.014
E2 (pg/ml) 53 (30-80) 50 (32-75) 0.811 31 (29-64) 45 (27-65) 0.647
E2-dhCG 1463 (944-1950) 1467 (923-2467) 0.523 1586 (1150-2029) 1242 (506-1765) 0.097
Follicle count 8 (6-10) 7 (4-9) 0.112 7 (4-10) 4 (3-10) 0.535
Results are reported as median and interquartile range.
Comparisons between groups were made using a Mann-Whitney test.
doi: 10.1371/journal.pone.0075685.t012
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Figure 4.  Absolute risk (risk rate) of clinical pregnancy rates as a function of AMH levels.  Patients were grouped according
to age or FSH levels. Rates are shown for serum AMH at 3, 6, 9, 12 and 15 pmol/L (equivalences for AMH in ng/mL are given at the
bottom of the figure). Dotted lines represent the 95% confidence interval.
doi: 10.1371/journal.pone.0075685.g004
Reproductive Outcomes According to Serum AMH
PLOS ONE | www.plosone.org 12 September 2013 | Volume 8 | Issue 9 | e75685
Author Contributions
Conceived and designed the experiments: SBO SDV MGB
RAR. Performed the experiments: SBO SDV EDM PB AMB
RAR. Analyzed the data: SBO SDV AF MGB RAR. Contributed
reagents/materials/analysis tools: SBO SDV EDM PB AMB
RAR. Wrote the manuscript: SBO SDV MGB AF RAR.
References
1. te Velde ER, Pearson PL (2002) The variability of female reproductive
ageing. Hum Reprod Update 8: 141-154. doi:10.1093/humupd/8.2.141.
PubMed: 12099629.
2. Nelson SM, Messow MC, McConnachie A, Wallace H, Kelsey T et al.
(2011) External validation of nomogram for the decline in serum anti-
Müllerian hormone in women: a population study of 15,834 infertility
patients. Reprod Biomed Online 23: 204-206: S1472-S6483.
11)00272-0 . PII . doi:10.1016/j.rbmo.2011.05.006
3. Broekmans FJ, Knauff EA, te Velde ER, Macklon NS, Fauser BC
(2007) Female reproductive ageing: current knowledge and future
trends. Trends Endocrinol Metab 18: 58-65. S1043- doi:10.1016/j.tem.
2007.01.004. PubMed: 17275321. 2760(07)00005-7 . PII . doi:10.1016/
j.tem.2007.01.004
4. Hendriks DJ, Kwee J, Mol BW, te Velde ER, Broekmans FJ (2007)
Ultrasonography as a tool for the prediction of outcome in IVF patients:
a comparative meta-analysis of ovarian volume and antral follicle count.
Fertil Steril 87: 764-775. S0015- doi:10.1016/j.fertnstert.2006.11.006.
PubMed: 17239869. 0282(06)04377-9 . PII . doi:10.1016/j.fertnstert.
2006.11.006
5. Broer SL, Mol BW, Hendriks D, Broekmans FJM (2009) The role of
antiMüllerian hormone in prediction of outcome after IVF: comparison
with the antral follicle count. Fertil Steril 91: 705-714. doi:10.1016/
j.fertnstert.2007.12.013. PubMed: 18321493.
6. Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB (2006) A
systematic review of tests predicting ovarian reserve and IVF outcome.
Hum Reprod Update 12: 685-718. doi:10.1093/humupd/dml034.
PubMed: 16891297.
7. Feyereisen E, Méndez Lozano DH, Taieb J, Hesters L, Frydman R et
al. (2006) Anti-Müllerian Hormone: clinical insights into a promising
biomarker of ovarian follicular status. Reprod Biomed Online 12:
695-703. doi:10.1016/S1472-6483(10)61081-4. PubMed: 16792844.
8. La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E et al. (2010)
Anti-Müllerian Hormone (AMH) as a predictive marker in assisted
reproductive technology (ART). Hum Reprod Update 16: 113-130. doi:
10.1093/humupd/dmp036. PubMed: 19793843. dmp036 . PII . doi:
10.1093/humupd/dmp036
9. Broer SL, Dólleman M, Opmeer BC, Fauser BC, Mol BW et al. (2011)
AMH and AFC as predictors of excessive response in controlled
ovarian hyperstimulation: a meta-analysis. Hum Reprod Update 17:
46-54. doi:10.1093/humupd/dmq034. PubMed: 20667894. dmq034 .
PII . doi:10.1093/humupd/dmq034
10. Anderson RA, Nelson SM, Wallace WH (2012) Measuring anti-
Müllerian hormone for the assessment of ovarian reserve: when and for
whom is it indicated? Maturitas 71: 28-33. doi:10.1016/
S0378-5122(12)70112-3. PubMed: 22119275.
11. Josso N, Picard JY, Rey R, di Clemente N (2006) Testicular Anti-
Müllerian Hormone: History, Genetics, Regulation and Clinical
Applications. Pediatr Endocrinol Rev 3: 347-358. PubMed: 16816803.
12. Vigier B, Picard JY, Tran D, Legeai L, Josso N (1984) Production of
anti-Müllerian hormone: another homology between Sertoli and
granulosa cells. Endocrinology 114: 1315-1320. doi:10.1210/
endo-114-4-1315. PubMed: 6546716.
13. Rey R, Sabourin JC, Venara M, Long WQ, Jaubert F et al. (2000) Anti-
Müllerian hormone is a specific marker of Sertoli- and granulosa-cell
origin in gonadal tumors. Hum Pathol 31: 1202-1208. doi:10.1053/
hupa.2000.18498. PubMed: 11070112.
14. Rey RA, Lhommé C, Marcillac I, Lahlou N, Duvillard P et al. (1996)
Antimüllerian hormone as a serum marker of granulosa cell tumors of
the ovary: comparative study with serum alpha-inhibin and estradiol.
Am J Obstet Gynecol 174: 958-965. doi:10.1016/
S0002-9378(96)70333-2. PubMed: 8633676.
15. Hagen CP, Aksglaede L, Sørensen K, Main KM, Boas M et al. (2010)
Serum levels of anti-Müllerian hormone as a marker of ovarian function
in 926 healthy females from birth to adulthood and in 172 Turner
syndrome patients. J Clin Endocrinol Metab 95: 5003-5010. doi:
10.1210/jc.2010-0930. PubMed: 20719830. jc.2010-0930 . PII . doi:
10.1210/jc.2010-0930
16. Fallat ME, Siow Y, Marra M, Cook C, Carrillo A (1997) Müllerian-
inhibiting substance in follicular fluid and serum: a comparison of
patients with tubal factor infertility, polycystic ovary syndrome, and
endometriosis. Fertil Steril 67: 962-965. doi:10.1016/
S0015-0282(97)81417-3. PubMed: 9130910.
17. Pigny P, Jonard S, Robert Y, Dewailly D (2006) Serum Anti-Müllerian
Hormone as a Surrogate for Antral Follicle Count for Definition of the
Polycystic Ovary Syndrome. J Clin Endocrinol Metab 91: 941-945.
PubMed: 16368745.
18. Long WQ, Ranchin V, Pautier P, Belville C, Denizot P et al. (2000)
Detection of minimal levels of serum anti-Müllerian hormone during
follow-up of patients with ovarian granulosa cell tumor by means of a
highly sensitive enzyme-linked immunosorbent assay. J Clin Endocrinol
Metab 85: 540-544. doi:10.1210/jc.85.2.540. PubMed: 10690852.
19. Cook CL, Siow Y, Taylor S, Fallat ME (2000) Serum Müllerian inhibiting
substance levels during normal mestrual cycles. Fertil Steril 73:
859-861. doi:10.1016/S0015-0282(99)00639-1. PubMed: 10731554.
20. La Marca A, Stabile G, Artenisio AC, Volpe A (2006) Serum anti-
Müllerian hormone throughout the human menstrual cycle. Hum
Reprod 21: 3103-3107. doi:10.1093/humrep/del291. PubMed:
16923748.
21. Hehenkamp WJK, Looman CWN, Themmen APN, de Jong FH, te
Velde ER et al. (2006) Anti-Müllerian Hormone Levels in the
Spontaneous Menstrual Cycle Do Not Show Substantial Fluctuation. J
Clin Endocrinol Metab 91: 4057-4063. doi:10.1210/jc.2006-0331.
PubMed: 16804046.
22. Josso N, Legeai L, Forest MG, Chaussain JL, Brauner R (1990) An
enzyme linked immunoassay for anti-Müllerian hormone: a new tool for
the evaluation of testicular function in infants and children. J Clin
Endocrinol Metab 70: 23-27. doi:10.1210/jcem-70-1-23. PubMed:
1688440.
23. Hudson PL, Dougas I, Donahoe PK, Cate RL, Epstein J et al. (1990)
An immunoassay to detect human mullerian inhibiting substance in
males and females during normal development. J Clin Endocrinol
Metab 70: 16-22. doi:10.1210/jcem-70-1-16. PubMed: 2294129.
24. Baker ML, Metcalfe SA, Hutson JM (1990) Serum levels of mullerian
inhibiting substance in boys from birth to 18 years, as determined by
enzyme immunoassay. J Clin Endocrinol Metab 70: 11-15. doi:10.1210/
jcem-70-1-11. PubMed: 2403569.
25. Rey RA, Belville C, Nihoul-Fékété C, Michel-Calemard L, Forest MG et
al. (1999) Evaluation of gonadal function in 107 intersex patients by
means of serum antimüllerian hormone measurement. J Clin
Endocrinol Metab 84: 627-631. doi:10.1210/jc.84.2.627. PubMed:
10022428.
26. Cook CL, Siow Y, Brenner AG, Fallat ME (2002) Relationship between
serum müllerian-inhibiting substance and other reproductive hormones
in untreated women with polycystic ovary syndrome and normal
women. Fertil Steril 77: 141-146. doi:10.1016/S0015-0282(01)02944-2.
PubMed: 11779604.
27. Fréour T, Mirallié S, Bach-Ngohou K, Denis M, Barrière P et al. (2007)
Measurement of serum Anti-Müllerian Hormone by Beckman Coulter
ELISA and DSL ELISA: Comparison and relevance in Assisted
Reproduction Technology (ART). Clin Chim Acta 375: 162-164. doi:
10.1016/j.cca.2006.06.013. PubMed: 16860302.
28. Fanchin R, Schonäuer LM, Righini C, Frydman N, Frydman R et al.
(2003) Serum anti-Müllerian hormone dynamics during controlled
ovarian hyperstimulation. Hum Reprod 18: 328-332. doi:10.1093/
humrep/deg043. PubMed: 12571169.
29. Grinspon RP, Ropelato MG, Bedecarrás P, Loreti N, Ballerini MG et al.
(2012) Gonadotrophin secretion pattern in anorchid boys from birth to
pubertal age: pathophysiological aspects and diagnostic usefulness.
Clin Endocrinol (Oxf) 76: 698-705. doi:10.1111/j.
1365-2265.2011.04297.x. PubMed: 22098623.
30. Olmedo SB, Rawe VY, Nodar FN, Galaverna GD, Acosta AA, Chemes
HE (2000) Pregnancies established through intracytoplasmic sperm
injection (ICSI) using spermatozoa with dysplasia of fibrous sheath.
Asian J Androl 2: 125-130. PubMed: 11232789.
31. Muttukrishna S, Suharjono H, McGarrigle H, Sathanandan M (2004)
Inhibin B and anti-Müllerian hormone: markers of ovarian response in
IVF/ICSI patients? BJOG: An International Journal of Obstetrics and
Gynaecology 111: 1248-1253. doi:10.1111/j.1471-0528.2004.00452.x.
PubMed: 15521870.
Reproductive Outcomes According to Serum AMH
PLOS ONE | www.plosone.org 13 September 2013 | Volume 8 | Issue 9 | e75685
32. Muttukrishna S, McGarrigle H, Wakim R, Khadum I, Ranieri DM et al.
(2005) Antral follicle count, anti-Müllerian hormone and inhibin B:
predictors of ovarian response in assisted reproductive technology?
BJOG 112: 1384-1390. doi:10.1111/j.1471-0528.2005.00670.x.
PubMed: 16167941.
33. Peñarrubia J, Fábregues F, Manau D, Creus M, Casals G et al. (2005)
Basal and stimulation day 5 anti-Müllerian hormone serum
concentrations as predictors of ovarian response and pregnancy in
assisted reproductive technology cycles stimulated with gonadotropin-
releasing hormone agonist-gonadotropin treatment. Hum Reprod 20:
915-922. PubMed: 15665015.
34. Ebner T, Sommergruber M, Moser M, Shebl O, Schreier-Lechner E et
al. (2006) Basal level of anti-Müllerian hormone is associated with
oocyte quality in stimulated cycles. Hum Reprod 21: 2022-2026. doi:
10.1093/humrep/del127. PubMed: 16679324.
35. McIlveen M, Skull JD, Ledger WL (2007) Evaluation of the utility of
multiple endocrine and ultrasound measures of ovarian reserve in the
prediction of cycle cancellation in a high-risk IVF population. Hum
Reprod 22: 778-785. PubMed: 17114197.
36. Smeenk JMJ, Sweep FCGJ, Zielhuis GA, Kremer JAM, Thomas CMG
et al. (2007) AntiMüllerian hormone predicts ovarian responsiveness,
but not embryo quality or pregnancy, after in vitro fertilization or
intracyoplasmic sperm injection. Fertil Steril 87: 223-226. doi:10.1016/
j.fertnstert.2006.06.019. PubMed: 17081531.
37. Nelson SM, Yates RW, Fleming R (2007) Serum anti-Müllerian
hormone and FSH: prediction of live birth and extremes of response in
stimulated cycles--implications for individualization of therapy. Hum
Reprod 22: 2414-2421. doi:10.1093/humrep/dem204. PubMed:
17636277. dem204 . PII . doi:10.1093/humrep/dem204
38. Fridén B, Sjöblom P, Menezes J (2011) Using anti-Müllerian hormone
to identify a good prognosis group in women of advanced reproductive
age. Aust N Z J Obstet Gynaecol 51: 411-415. doi:10.1111/j.
1479-828X.2011.01374.x. PubMed: 21988118.
39. Jayaprakasan K, Campbell B, Hopkisson J, Johnson I, Raine-Fenning
N (2010) A prospective, comparative analysis of anti-Müllerian
hormone, inhibin-B, and three-dimensional ultrasound determinants of
ovarian reserve in the prediction of poor response to controlled ovarian
stimulation. Fertil Steril 93: 855-864. doi:10.1016/j.fertnstert.
2008.10.042. PubMed: 19046583.
40. Seifer DB, MacLaughlin DT, Christian BP, Feng B, Shelden RM (2002)
Early follicular serum müllerian-inhibiting substance levels are
associated with ovarian response during assisted reproductive
technology cycles. Fertil Steril 77: 468-471. doi:10.1016/
S0015-0282(01)03201-0. PubMed: 11872196.
41. Hazout A, Bouchard P, Seifer DB, Aussage P, Junca AM et al. (2004)
Serum antimullerian hormone/mullerian-inhibiting substance appears to
be a more discriminatory marker of assisted reproductive technology
outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertil
Steril 82: 1323-1329. doi:10.1016/j.fertnstert.2004.03.061. PubMed:
15533354.
42. Silberstein T, MacLaughlin DT, Shai I, Trimarchi JR, Lambert-
Messerlian G et al. (2006) Mullerian inhibiting substance levels at the
time of HCG administration in IVF cycles predict both ovarian reserve
and embryo morphology. Hum Reprod 21: 159-163. doi:10.1093/
oxfordjournals.humrep.a002489. PubMed: 16123085.
43. Lekamge DN, Barry M, Kolo M, Lane M, Gilchrist RB, Tremellen KP
(2007) Anti-Müllerian Hormone as a predictor of IVF outcome. Reprod
Biomed Online 14: 602-610. doi:10.1016/S1472-6483(10)61053-X.
PubMed: 17509203.
44. Lie Fong S, Baart EB, Martini E, Schipper I, Visser JA et al. (2008) Anti-
Müllerian Hormone: a marker for oocyte quantity, oocyte quality and
embryo quality? Reprod Biomed Online 16: 664-670. doi:10.1016/
S1472-6483(10)60480-4. PubMed: 18492370.
Reproductive Outcomes According to Serum AMH
PLOS ONE | www.plosone.org 14 September 2013 | Volume 8 | Issue 9 | e75685
